International Journal of Research in Medical Sciences
Paudel R. Int J Res Med Sci. 2023 Jul;11(7):2745-2749
www.msjonline.org
pISSN 2320-6071 | eISSN 2320-6012

DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20232138

Review Article

Current understanding and management of clostridioides difficile infection: an overview

Rama Paudel*

School of Biomedical Sciences, Trinity Medical Sciences University, Kingstown, St. Vincent and the Grenadines

Received: 18 May 2023
Accepted: 09 June 2023

***Correspondence:**
Dr. Rama Paudel,
E-mail: paudelnepal.rama@gmail.com

ABSTRACT

Clostridiodes difficile infection (CDI) is a major cause of healthcare-associated infections worldwide, with a significant morbidity and mortality. The incidence of this infection has been increasing in recent years, particularly among elderly patients and those with comorbidities. The pathogenesis of CDI involves the disruption of the gut microbiota, followed by the production of toxins that lead to colonic inflammation and tissue damage. The clinical presentation varies from mild diarrhea to severe pseudomembranous colitis, toxic megacolon, and sepsis. The diagnosis of CDI is based on the presence of clinical symptoms, laboratory testing, and imaging studies. The treatment of CDI involves antimicrobial therapy, supportive care, and infection control measures. Recently, there have been significant developments in the management of CDI, including the use of fidaxomicin, fecal microbiota transplantation (FMT), and monoclonal antibodies. This manuscript reviews the epidemiology, pathogenesis, clinical presentation, diagnosis and updated guidelines for the management of CDI.

Keywords: CDI, Pathogenesis, Clinical presentation, Diagnosis, Management

INTRODUCTION

Clostridiodes difficile (formerly known as clostridium difficile) is a Gram-positive, anaerobic, spore-forming bacterium that is a leading cause of healthcare-associated infections worldwide.[1] The incidence of CDI has been increasing in recent years, with an estimated 500,000 cases and 29,000 deaths in the United States annually.[2] CDI is associated with significant morbidity and mortality, particularly among elderly patients and those with comorbidities such as inflammatory bowel disease, cancer, and renal failure.[3]

The pathogenesis of CDI is complex and involves the disruption of the normal gut microbiota, the production of toxins A and B, and the activation of the host immune response.[4] The clinical presentation of CDI varies from mild diarrhea to severe colitis, toxic megacolon, and sepsis. The diagnosis of CDI is based on the presence of clinical symptoms, laboratory testing, and imaging studies. The treatment of CDI involves antimicrobial therapy, supportive care and the infection control measures.

In recent years, there have been significant developments in the management of CDI, including the use of fidaxomicin, FMT, and monoclonal antibodies. This manuscript reviews the epidemiology, pathogenesis, clinical presentation, diagnosis and updated guidelines for the management of CDI.

EPIDEMIOLOGY

CDI is a major cause of healthcare-associated infections worldwide, particularly in hospitals and long-term care facilities.[5] The incidence of CDI has been increasing in recent years, with a rise in community-acquired CDI and a shift towards more virulent strains, such as the NAP1/BI/027 strain.[6] The incidence of CDI is highest among elderly patients and those with comorbidities, with

rates of up to 30% in hospitalized patients over the age of 65.[6]

Several risk factors are associated with the development of CDI, including antimicrobial use, proton pump inhibitors, immunosuppressive therapy, and previous hospitalization.[7] The use of broad-spectrum antibiotics, such as clindamycin, fluoroquinolones, and cephalosporins, is a major risk factor for CDI, as these agents disrupt the normal gut microbiota and allow for the overgrowth of C. difficile.[8]

PATHOGENESIS

The pathogenesis of CDI involves the disruption of the gut microbiota, followed by the production of toxins that lead to colonic inflammation and tissue damage. C. difficile spores are resistant to environmental stress and can persist in the environment for extended periods.[9] When a susceptible host ingests C. difficile spores, the spores germinate and proliferate in the colon, leading to the production of two toxins, toxin A and toxin B.[9] These toxins cause diarrhea, colonic inflammation, and mucosal damage. In addition, some strains of C. difficile produce a third toxin, binary toxin, which has been associated with increased severity of CDI.[10] The pathogenesis of CDI is complex and involves a variety of host and bacterial factors, including the host immune response, bacterial virulence factors, and environmental factors such as antibiotic use and hospitalization.[6]

CLINICAL PRESENTATION

The clinical presentation of CDI varies from mild diarrhea to severe pseudomembranous colitis (which is characterized by the presence of yellow-white plaques on the intestinal mucosa), toxic megacolon, and sepsis. The onset of symptoms usually occurs within one to two weeks after exposure to C. difficile.[11]

The most common symptom of CDI is diarrhea, which may be watery, bloody, or mucoid, and is often associated with abdominal cramping, fever, and leukocytosis.[12] In severe cases, patients may develop toxic megacolon, a life-threatening complication characterized by abdominal distention, fever, hypotension, and altered mental status.[12]

CDI can also present as recurrent episodes of diarrhea, which are defined as the recurrence of symptoms within 8 weeks of the initial episode and with the same or a different strain of C. difficile.[13] Recurrent CDI is associated with a higher morbidity and mortality and is more difficult to treat than the initial episode.[13]

DIAGNOSIS

The diagnosis of CDI is based on the presence of clinical symptoms, laboratory testing, and imaging studies.[6,11] The clinical suspicion of CDI should be high in patients with risk factors and symptoms suggestive of CDI, such as diarrhea, abdominal pain, and fever.

Laboratory testing for CDI includes the detection of toxins A and B in stool samples using enzyme immunoassays (EIA) or nucleic acid amplification tests (NAATs).[14] The sensitivity and specificity of these tests vary widely and depend on the type of assay used, the prevalence of CDI in the population, and the timing of the test relative to symptom onset.[14] The use of molecular tests, such as polymerase chain reaction (PCR), can improve the sensitivity of CDI diagnosis, but may also lead to the detection of asymptomatic colonization or non-toxigenic strains of C. difficile.[15]

Imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be useful in patients with severe or complicated CDI, to assess for the presence of toxic megacolon, perforation, or abscess.[16] Colonoscopy may also be useful in the diagnosis of CDI, to visualize the presence of pseudomembranes, which are a hallmark of severe colitis.[17]

UPDATED GUIDELINES FOR THE MANAGEMENT OF CDI

The management of CDI involves antimicrobial therapy, supportive care, and infection control measures. Recently, there have been significant developments in the management of CDI, including the use of fidaxomicin, FMT, and monoclonal antibodies. The following section reviews updated guidelines for the management of CDI.

Antimicrobial therapy

The treatment of CDI involves the use of antimicrobial therapy, with the goal of eradicating C. difficile and reducing the risk of recurrence. The choice of antimicrobial agent depends on the severity of CDI, the risk of recurrence, and the local antibiotic susceptibility patterns.

Mild to moderate CDI can be treated with oral metronidazole or oral vancomycin, which are equally effective in eradicating C. difficile and preventing recurrence.[3,11,16] The duration of therapy is typically 10-14 days, although longer courses may be necessary in severe or complicated cases.

Severe or complicated CDI requires more aggressive therapy, with the use of intravenous (IV) metronidazole or oral vancomycin in high doses.[11,16] Vancomycin has been found to be superior to metronidazole for treatment of severe CDI.[18] In cases of toxic megacolon or ileus, oral therapy may be ineffective, and IV vancomycin or a combination of IV metronidazole and oral vancomycin should be considered.[19] The duration of therapy in severe cases may be longer, up to 6 weeks or more, depending on the clinical response.

Fidaxomicin is a newer antimicrobial agent that has been shown to be non-inferior to oral vancomycin in the treatment of CDI, with a lower risk of recurrence.[19,20] Fidaxomicin has a narrow spectrum of activity and is less likely to disrupt the gut microbiome, which may contribute to its lower recurrence rate.[20] Fidaxomicin is recommended as an alternative to oral vancomycin in patients with recurrent CDI or in those at high risk of recurrence.[11]

Supportive care

Supportive care plays a vital role in CDI management. The supportive measures include various interventions aimed at managing symptoms and preventing complications. The following are commonly employed supportive measures for CDI.[11]

Hydration: Patients with CDI are at risk of dehydration due to diarrhea. Adequate hydration is crucial to maintain fluid balance. Oral rehydration solutions or intravenous fluids may be administered as needed.

Electrolyte replacement: CDI can lead to electrolyte imbalances, such as low levels of potassium, sodium, and magnesium. Monitoring and correcting these imbalances through appropriate electrolyte replacement is very important.

Nutritional support: Maintaining adequate nutrition is essential in CDI management. In severe cases or when oral intake is limited, enteral nutrition or parenteral nutrition may be considered.

Symptom management: Medications to control diarrhea and alleviate abdominal discomfort may be used, although antimotility agents are generally avoided as they may prolong the infection.

Discontinuation of unnecessary antibiotics: If the patient is taking antibiotics that are not essential, they may be discontinued to reduce the disruption of the gut microbiota and the risk of CDI recurrence.

Infection control measures

Infection control measures are essential in the prevention and control of CDI. Standard precautions, such as hand hygiene, contact precautions, and environmental cleaning, are effective in reducing the transmission of C. difficile in healthcare settings.[11,21]

Patients with CDI should be placed on contact precautions, with the use of gowns and gloves, to prevent the spread of spores to healthcare workers and other patients.[21] Environmental cleaning with a sporicidal agent, such as bleach or hydrogen peroxide, is necessary to eliminate C. difficile spores from contaminated surfaces.[22]

Other strategies

FMT

FMT involves the transfer of fecal material from a healthy donor into the gastrointestinal tract of a recipient, with the goal of restoring the balance of the gut microbiome and eradicating C. difficile.[11,23] FMT has emerged as a highly effective treatment for recurrent CDI, with a cure rate of over 90% in most studies.[11,23]

FMT can be performed via several routes, including colonoscopy, nasogastric tube, or enema. The optimal route of administration depends on the severity of CDI, the presence of comorbidities, and the patient's preference.

FMT is generally considered safe, with a low risk of adverse events. However, there have been rare reports of transmission of infectious agents, such as multi-drug resistant bacteria or viral pathogens.[23] The use of standardized donor screening and testing protocols, as well as rigorous monitoring of recipients, can minimize these risks.

Monoclonal antibodies

Monoclonal antibodies against C. difficile toxins have emerged as a promising adjunctive therapy for CDI.[11,24] Bezlotoxumab is a monoclonal antibody against toxin B that has been shown to reduce the risk of recurrence in patients with CDI.[24] Bezlotoxumab is given as a single IV infusion at the time of initial antibiotic therapy and has been shown to reduce the risk of recurrence by up to 40%. However, bezlotoxumab is expensive and may not be available in all healthcare settings.

Probiotics

The use of probiotics, such as *Lactobacillus rhamnosus* GG and *Saccharomyces boulardii*, as adjunctive therapy, has shown some potential benefits in reducing the recurrence of CDI.[11] However, further research is needed to establish clear recommendations regarding their use.

Prevention strategies

Preventing CDI requires a multifaceted approach, including antimicrobial stewardship programs, proper hand hygiene, environmental cleaning, and judicious use of antibiotics.[11] Vaccines targeting C. difficile toxins are also being developed and show promise for future prevention efforts.

CONCLUSION

CDI remains a significant healthcare-associated infection, with a high burden of morbidity and mortality. Recent advances in the management of CDI, including the use of fidaxomicin, FMT, and monoclonal antibodies, have

improved the outcomes for patients with CDI. Infection control measures, such as hand hygiene and environmental cleaning, are essential in the prevention and control of CDI in healthcare settings. It is important to note that the optimal management of CDI depends on several factors, including the severity of disease, the risk of recurrence, and the local antibiotic susceptibility patterns. Clinicians should consider the individual patient's clinical and microbiological characteristics when selecting the appropriate treatment regimen. Future directions in the management of CDI include the development of novel antimicrobial agents with a narrower spectrum of activity, the identification of biomarkers for the early diagnosis and prediction of disease outcomes, and the development of vaccines against C. difficile toxins.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J et al. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. N Engl J Med. 2018;379(18):1732-44.
2. Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320-30.
3. McFarland LV. Epidemiology, risk factors and treatments for Clostridium difficile infection. Ther Adv Infect Dis. 2016;3(2-3):61-75.
4. Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol. 2015;69:445-61.
5. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-208.
6. Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;372(6):1539-48.
7. Guh AY, Kutty PK. Clostridioides difficile Infection. Anna Internal Med. 2018;169(7):ITC49-64.
8. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrobial Agents Chemotherapy. 2013;57(5):2326-32.
9. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis. 2014;209(1):83-6.
10. Martinez-Melendez A, Cruz-Lopez F, Morfin-Otero R, Maldonado-Garza HJ, Garza-Gonzalez E. An Update on Clostridioides difficile Binary Toxin. Toxins. 2022;14(5):305.
11. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-48.
12. Lamont JT, Kelly CP, Bakken JS. Clostridioides difficile infection in adults: Clinical manifestations and diagnosis. UpToDate. 2021. Available at: https://www.uptodate.com/contents/clostridioides-difficile-infection-in-adults-clinical-manifestations-and-diagnosis. Accessed on May 16, 2023.
13. Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver. 2019;13(1):16-24.
14. Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(4):S63-81.
15. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792-801.
16. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-98.
17. Salen P, Stankewicz HA. Pseudomembranous Colitis. Stat Pearls. Available at: https://www.ncbi.nlm.nih.gov/books/NBK470319/#:~:text=Colonoscopies%20of%20patients%20with%20pseudomembranous,surface%20of%20the%20colonic%20mucosa. Accessed on May 16, 2023
18. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-7.
19. Oldfield EC IV, Oldfield EC III, Johnson DA. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther. 2014;5(1):1-26.
20. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-9.
21. Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(2):S48-65.
22. Anderson DJ, Chen LF, Weber DJ, Moehring RW, Lewis SS, Triplett PF et al. Enhanced terminal room disinfection and acquisition and infection caused by

multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study. Lancet. 2017;389(10071):805-14.
23. Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80.
24. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-17.

Cite this article as: Paudel R. Current understanding and management of clostridioides difficile infection: an overview. Int J Res Med Sci 2023;11:2745-9.